Rigor Reviewed

Rigor-Reviewed Manuscript

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.

Name: Αlpha¹ Rigor Record — Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
Item: Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
Rating: 96
Author: Αlpha¹

Pratley RE, Denham DS, Trivedi R, Watkins E, Connery L, Barnes J, Yu D, Hong J, Simard C, Umans K, Liu L, Tirucherai GS, Marantz JL

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1.75★ (Critical), 0 critical, 3 high issues for “Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1.75 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 2 randomized controlled trial with a clear scientific premise, rigorous design, and transparent reporting. The main weaknesses are a vague data availability statement and minor reporting gaps (outlier handling, model assumptions, explicit reporting guideline).

Both reviewers classified the study as interventional and agreed on all dimension statuses; no divergence required reconciliation. The statistics verification recomputed only 2 tests (those with test statistics/df or effect+CI); the rest of the statistical results are unverified. The citation check found no retracted or unresolved references. The preregistration check confirmed registration on ClinicalTrials.gov, but the integrity check noted the registration was submitted after the study start date (retrospective registration).

8 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on incretin mimetics and lean mass loss, and on myostatin biology and prior failed attempts at targeting myostatin, noting reasons such as off-target effects and suboptimal trial design. The rationale linking myostatin inhibition to lean mass preservation is logical and leads to the study objective. The paper also addresses limitations of prior research by highlighting the selective mechanism of apitegromab and appropriate trial design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise: incretin mimetic therapies cause lean mass loss, and myostatin inhibition may preserve lean mass. Prior work is cited and limitations of prior myostatin-targeting attempts are acknowledged.

Evidence

paraphrase[Introduction, paragraph 1]

“Incretin mimetic therapy is accompanied by a loss of lean body mass that accounts for approximately 25−40% of total weight loss.”

paraphrase[Introduction, paragraph 3]

“Reasons for this include off-target side effects due to lack of target selectivity or inability to demonstrate efficacy due to inappropriate choice of disease or suboptimal trial design.”

direct quote[Introduction, paragraph 3]

“Apitegromab is an investigational, fully human monoclonal antibody that selectively binds precursor forms of myostatin to potently inhibit myostatin activation, without activity toward other TGFβ superfamily members.”